Becton Dickinson vs. Beckman Coulter: Fluorescent Dye Patent Dispute Ends in Mutual Dismissal
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Becton, Dickinson and Company v. Beckman Coulter, Inc. |
| Numéro de dossier | 3:21-cv-01173 (S.D. Cal.) |
| Tribunal | Tribunal fédéral de première instance pour le district sud de Californie |
| Durée | June 2021 – July 2024 3 years |
| Résultat | Mutual Dismissal With Prejudice |
| Legal Reps | Plaintiffs: Barbara A. Fiacco (Foley Hoag LLP) Defendant: David M. Krinsky (Williams & Connolly LLP) |
| Brevets en cause | |
| Produits incriminés | Beckman Coulter’s SuperNova Dyes and corresponding dye-antibody conjugates |
Aperçu du dossier
Les parties
⚖️ Demandeurs
A global medical technology leader with extensive IP holdings in diagnostics and life sciences instrumentation. Co-plaintiffs Sirigen, Inc. and Sirigen II Limited are BD subsidiaries specializing in conjugated polymer dye technologies.
🛡️ Défendeur
A Danaher Corporation subsidiary and major competitor in flow cytometry instrumentation and reagent systems. Its SuperNova Dye line directly competes with BD’s Brilliant dye products.
Brevets en cause
This case involved 13 U.S. patents covering conjugated polymer fluorescent dye technologies, foundational to modern multi-parameter flow cytometry panels. These patents collectively protect the synthesis, composition, and application of **conjugated polymer-based fluorescent dyes** and **dye-antibody conjugates**.
- • US10641775B2 | US9139869B2 | US8362193B2
- • US10302648B2 | US10288620B2 | US8455613B2
- • US9547008B2 | US10955417B2 | US8575303B2
- • US10458989B2 | US10962546B2 | US10094838B2
- • US10365285B2
Developing a new fluorescent dye or reagent?
Check if your product might infringe these or related patents before launch.
Le verdict et l'analyse juridique
Résultat
On July 12, 2024, the parties filed a **Joint Motion and Stipulation of Dismissal** pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii). The court granted the motion, ordering plaintiffs’ claims and defendant’s counterclaims dismissed **with prejudice**, with each party bearing its own costs. No damages award was disclosed, and no injunctive relief was ordered, strongly suggesting a **confidential settlement agreement**.
Principales questions juridiques
The litigation centered on **patent infringement** across 13 conjugated polymer dye patents. Beckman Coulter’s litigation posture likely included invalidity counterclaims, potentially challenging patents on grounds of prior art or enablement. The breadth of the patent portfolio asserted created comprehensive infringement exposure. The dismissal with prejudice of Beckman Coulter’s counterclaims precludes re-litigation of those specific challenges, a meaningful concession that may have formed part of settlement negotiations.
While the case produced no published claim construction ruling or validity determination, its significance lies in the strategic use of a broad patent portfolio for litigation leverage and the ultimate resolution through a mutual Rule 41 dismissal, which permanently extinguishes all claims and counterclaims.
Analyse de la liberté d'exploitation (FTO)
This case highlights critical IP risks in the fluorescent dye and reagent space. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- View all 13 asserted patents in this technology space
- See which companies are most active in fluorescent dyes
- Understand conjugated polymer dye claim patterns
🔍 Vérifier les risques liés à mon produit
Effectuez une analyse FTO complète pour votre propre technologie ou produit.
- Saisissez la description de votre produit ou ses caractéristiques techniques.
- L'IA identifie les brevets susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
Conjugated polymer dye compositions
13 brevets revendiqués
In fluorescent dye space
Résolution stratégique
Via confidential settlement
✅ Points clés à retenir
Thirteen-patent portfolio assertions create compounding invalidity burdens for defendants and substantial settlement leverage for plaintiffs.
Rechercher la jurisprudence connexe →Dismissal with prejudice of counterclaims extinguishes invalidity challenges permanently — a critical negotiating point in settlement discussions.
Explorer les précédents →Rule 41(a)(1)(A)(ii) joint dismissals in complex patent cases frequently signal confidential commercial resolutions.
Understand procedural dynamics →Foire aux questions
The case involved 13 U.S. patents (including US10641775B2, US9139869B2, US8362193B2, and ten additional patents) covering conjugated polymer fluorescent dye technologies assigned to Becton Dickinson and its Sirigen subsidiaries.
Both parties filed a joint stipulation of dismissal under FRCP Rule 41(a)(1)(A)(ii) on July 12, 2024, indicating a mutually agreed resolution. Dismissal with prejudice permanently bars re-litigation of the same claims.
The unresolved judicial record leaves BD’s 13-patent portfolio legally intact and untested by verdict, maintaining ongoing IP risk for competitors developing conjugated polymer dye technologies in the flow cytometry reagent market.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- PACER Case Lookup – Case No. 3:21-cv-01173
- Base de données en texte intégral des brevets de l'USPTO
- Southern District of California Court Records
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.